Dr Andrew Mearns Spragg is a marine biotechnology pioneer and entrepreneur with >25years’ experience in company creation and marine biotechnology innovation. His entrepreneurial achievements include raising to date over >£30M in equity finance from VCs and Angels and receiving the 2007 Gannochy Award and Medal from the Royal Society of Edinburgh, Scotland’s highest award for Innovation.

He currently the Founder & Chief Scientific Officer of Jellagen Ltd, a med-tech company developing collagen Type Zero derived from jellyfish, a fundamentally transformational new class of collagen: non-mammalian, sustainably sourced, and engineered to expand what’s possible in wound care, soft tissue repair, and regenerative medicine. Andrew established Jellagen's in-house collagen standards and first data sets and also helped build the world's first ISO13485:2016 certified manufacturing plant to produce this innovative biomaterial directed towards developing new medical device and tissue engineering innovation. Andrew is a member of the Executive Committee, responsible for Scientific and Technology strategy, Product and Business Development activities.

Andrew was a member of Scotland’s Life Science Advisory Board (2009-2011) and elected to the Royal Society of Edinburgh’s Young Academy from 2011 – 2015. He was made Honorary Professorships from the University of Stirling (2012-2016) and University of the Highlands and Islands (2012 – Present). He is a Fellow of the Royal Society of Biology, Chemistry and Encouragement of Arts, Manufactures and Commerce. He holds a first-class BSc degree in Microbiology and PhD in Marine Biotechnology from Heriot-Watt University, Edinburgh, UK.